Developer docs
API playgroundTry for free, no card

Search company profiles

Gadeta

Full company profile

uuid0003n6a

Namestring
Gadeta
Websiteurl
gadeta.nl
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Gadeta is a Utrecht-based biotech developing engineered T-cell receptor immunotherapies for cancer. Founded in 2015, it is a preclinical, venture-funded R&D company backed by Baxalta Ventures, Medicxi, Utrecht Holdings, and Kite Pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, gamma delta T cells, cell therapy R&D, T cell receptor engineering, biopharmaceutical development
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Cell Therapy / Gamma Delta T Cell Immunotherapy R&D
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Gadeta is a research and development biopharmaceutical company developing immunotherapies for cancer, centered on a proprietary gamma delta (γδ) T cell receptor technology platform. The company engineers γδ T cell receptors to create novel cell therapies targeting solid and hematological malignancies, with a focus on allogeneic, off-the-shelf treatment approaches. Its work combines TCR discovery, receptor engineering, and preclinical cell therapy development in collaboration with strategic pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Gamma delta T cell receptor (γδ TCR) immunotherapy platform
CategoryCancer cell therapy R&D platform
Description

A proprietary research and development platform based on gamma delta T cell receptor engineering, used to discover and develop novel allogeneic cancer cell therapies targeting solid and hematological malignancies. Intended for strategic partnership and licensing with pharmaceutical companies developing oncology pipelines.

Partnership1 partner
Strategic tierMinorTypeOthers
Description

Greenhost provides web hosting services for Gadeta's website (gadeta.nl). This is an infrastructure/vendor relationship where Greenhost acts as the hosting provider.

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing TCR-T cell therapies for solid tumors. Most direct comparable to Gadeta given overlapping TCR-engineered autologous cell therapy modality and oncology focus.

TypeDirect peer
Description

Develops allogeneic and autologous gamma-delta T-cell therapies for cancer. Closest mechanistic peer to Gadeta, as both pursue gamma-delta biology in oncology cell therapy.

TypeDirect peer
Description

Develops TCR-based immunotherapies against tumor-specific antigens. Comparable on the TCR-T modality and oncology focus, with a broader multi-platform approach.

TypeEmerging player
Description

Pioneers allogeneic CAR-T and gene-edited cell therapies using TALEN. Comparable as an engineered cell therapy developer, though focused on allogeneic CAR-T rather than TCR-T.

TypeBroad incumbent
Description

Leading allogeneic CAR-T developer. Comparable as a large, well-capitalized engineered cell therapy company competing for talent, sites, and partnerships in the same oncology cell therapy space.

TypeEmerging player
Description

Develops iPSC-derived NK and T-cell therapies. Comparable as an engineered cell therapy platform company pursuing off-the-shelf oncology indications.

TypeEmerging player
Description

Develops TCR-based ImmTAC molecules for oncology. Comparable as a TCR-based oncology platform, though delivers TCRs as soluble biologics rather than cell therapies.

TypeBroad incumbent
Description

Gene-edited cell therapy developer (Casgevy partner with Vertex). Comparable as a major engineered cell therapy player and potential competitor for clinical-stage assets and partnership capital.

TypeEmerging player
Description

Develops in vivo and ex vivo gene-edited cell therapies using ARCUS nucleases. Comparable as a gene-edited cell therapy developer in oncology.

TypeBroad incumbent
Description

Commercial leader in autologous CAR-T cell therapy and an existing investor in Gadeta. Comparable as the strategic acquirer/partner with manufacturing scale that anchors cell therapy economics in oncology.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gadeta

Cancer Cell Therapy / Gamma Delta T Cell Immunotherapy R&Dgadeta.nl

Gadeta is a Utrecht-based biotech developing engineered T-cell receptor immunotherapies for cancer. Founded in 2015, it is a preclinical, venture-funded R&D company backed by Baxalta Ventures, Medicxi, Utrecht Holdings, and Kite Pharma.

Gadeta firmographics

Firmographics
Name
Gadeta
Website
https://gadeta.nl
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Gadeta is a Utrecht-based biotech developing engineered T-cell receptor immunotherapies for cancer. Founded in 2015, it is a preclinical, venture-funded R&D company backed by Baxalta Ventures, Medicxi, Utrecht Holdings, and Kite Pharma.
Ownership category
akta.pro rank

Gadeta industry classification

Industry
Product category
Cancer Cell Therapy / Gamma Delta T Cell Immunotherapy R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cancer immunotherapy
  • Gamma delta T cells
  • Cell therapy R&D
  • T cell receptor engineering
  • Biopharmaceutical development

Where Gadeta is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Markets served

Gadeta business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Gadeta product offering

Product offering

Core offering

Gadeta is a research and development biopharmaceutical company developing immunotherapies for cancer, centered on a proprietary gamma delta (γδ) T cell receptor technology platform. The company engineers γδ T cell receptors to create novel cell therapies targeting solid and hematological malignancies, with a focus on allogeneic, off-the-shelf treatment approaches. Its work combines TCR discovery, receptor engineering, and preclinical cell therapy development in collaboration with strategic pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gamma delta T cell receptor (γδ TCR) immunotherapy platform A proprietary research and development platform based on gamma delta T cell receptor engineering, used to discover and develop novel allogeneic cancer cell therapies targeting solid and hematological malignancies. Intended for strategic partnership and licensing with pharmaceutical companies developing oncology pipelines.

Companies that use Gadeta

Customer profile

Ideal customer profiles1 record

Gadeta technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Gadeta partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GreenhostminorOthersGreenhost provides web hosting services for Gadeta's website (gadeta.nl). This is an infrastructure/vendor relationship where Greenhost acts as the hosting provider.

Gadeta competitors and assessment

Company assessment

Direct peers

  • Adaptimmune: Clinical-stage company developing TCR-T cell therapies for solid tumors. Most direct comparable to Gadeta given overlapping TCR-engineered autologous cell therapy modality and oncology focus.
  • TC BioPharm: Develops allogeneic and autologous gamma-delta T-cell therapies for cancer. Closest mechanistic peer to Gadeta, as both pursue gamma-delta biology in oncology cell therapy.
  • Immatics: Develops TCR-based immunotherapies against tumor-specific antigens. Comparable on the TCR-T modality and oncology focus, with a broader multi-platform approach.

Emerging players

  • Cellectis: Pioneers allogeneic CAR-T and gene-edited cell therapies using TALEN. Comparable as an engineered cell therapy developer, though focused on allogeneic CAR-T rather than TCR-T.
  • Fate Therapeutics: Develops iPSC-derived NK and T-cell therapies. Comparable as an engineered cell therapy platform company pursuing off-the-shelf oncology indications.
  • Immunocore: Develops TCR-based ImmTAC molecules for oncology. Comparable as a TCR-based oncology platform, though delivers TCRs as soluble biologics rather than cell therapies.
  • Precision BioSciences: Develops in vivo and ex vivo gene-edited cell therapies using ARCUS nucleases. Comparable as a gene-edited cell therapy developer in oncology.

Broad incumbents

  • Allogene Therapeutics: Leading allogeneic CAR-T developer. Comparable as a large, well-capitalized engineered cell therapy company competing for talent, sites, and partnerships in the same oncology cell therapy space.
  • CRISPR Therapeutics: Gene-edited cell therapy developer (Casgevy partner with Vertex). Comparable as a major engineered cell therapy player and potential competitor for clinical-stage assets and partnership capital.
  • Kite Pharma (a Gilead Company): Commercial leader in autologous CAR-T cell therapy and an existing investor in Gadeta. Comparable as the strategic acquirer/partner with manufacturing scale that anchors cell therapy economics in oncology.

Market position

Customer concentration

Gadeta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gadeta leadership team

Management profile

Number of profiles

Profiles4 records

Gadeta funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gadeta M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gadeta

What does Gadeta do?

Gadeta is a research and development biopharmaceutical company developing immunotherapies for cancer, centered on a proprietary gamma delta (γδ) T cell receptor technology platform. The company engineers γδ T cell receptors to create novel cell therapies targeting solid and hematological malignancies, with a focus on allogeneic, off-the-shelf treatment approaches. Its work combines TCR discovery, receptor engineering, and preclinical cell therapy development in collaboration with strategic pharmaceutical partners.

When was Gadeta founded?

Gadeta was founded in 2015. It employs 11 to 50 people.

Where is Gadeta based?

Gadeta is headquartered in Utrecht, Netherlands, in the Europe region.

Who are Gadeta's main competitors?

Direct peers on record are Adaptimmune, TC BioPharm and Immatics. Emerging players are Cellectis, Fate Therapeutics, Immunocore and Precision BioSciences. Broad incumbents are Allogene Therapeutics, CRISPR Therapeutics and Kite Pharma (a Gilead Company).

Does Gadeta have an API?

No public API is recorded for Gadeta.

What industry is Gadeta in?

Gadeta's product category is Cancer Cell Therapy / Gamma Delta T Cell Immunotherapy R&D. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireClade Therapeutics Announces the Acquisition of Gadeta B.V.Clade Therapeutics completed the acquisition of Gadeta B.V., a cell therapy company developing gamma/delta TCR-based immunotherapies for cancer. The deal integrates Gadeta's g/d TCR discovery engine and preclinical programs into Clade's solid tumor pipeline, with shareholders receiving upfront and downstream economics.SynconaltdClade Therapeutics Announces the Acquisition of Gadeta B.V.Clade Therapeutics has completed the acquisition of Gadeta B.V., integrating its proprietary gamma/delta TCR universal targeting platform technology into Clade's solid tumor pipeline. This strategic move expands Clade’s capabilities by adding preclinical cell therapy programs and a discovery engine to its existing cellular platform. The transaction makes Gadeta a wholly owned subsidiary, allowing Clade to develop more robust off-the-shelf stem-cell-based medicines.GlobeNewswireImmunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid TumorsImmunocore and Gadeta announced a collaboration to develop the first gamma delta TCR ImmTAC for solid tumors, including colorectal cancer. Gadeta's TCR '201 targets a non-HLA restricted signal, with a Phase 1 trial for GDT201 planned in H2 2023. Immunocore has an option for an exclusive license to develop and commercialize ImmTAC candidates.PR NewswireGadeta Appoints Scientific Advisory Board and Provides Business UpdateGadeta B.V. announced the formation of a Scientific Advisory Board chaired by Dr. Hagop Youssoufian and comprising five internationally recognized leaders in oncology and T-cell biology from institutions including Memorial Sloan Kettering, Stanford, Monash University, and MD Anderson Cancer Center. The company is progressing two solid tumor cell therapy programs toward clinical trials, with GDT002 already having an open IND and GDT201 planned for a Phase I trial in H2 2023. Gadeta also disclosed plans to scale up its NOVA γδ TCR discovery platform to build a pipeline of first-in-class TCR immunotherapies targeting solid tumors.PR NewswireGadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific ConferencesGadeta B.V., a clinical-stage immunotherapy company based in Utrecht, Netherlands, announced that its CEO and CSO will present preclinical data on gamma delta TCR-based cell therapies at the Innate Natural Killer Summit 2022 in San Diego and the AACR Annual Meeting 2022 in New Orleans. The company's lead candidate GDT002 demonstrated potent anti-tumor activity across a broad spectrum of solid and liquid tumors, leading to the selection of ovarian cancer as the indication for its upcoming Phase 1/2 clinical trial. The company also reported that GDT201 is progressing through IND-enabling studies for colorectal cancer, with preclinical data showing 100% complete response in xenograft models.PR NewswireGadeta announces significant progress in advancing pipeline and TEG platform developmentGadeta announced progress on its gamma delta TCR-based immunotherapies, with phase 1/2 trials for GDT002 in multiple myeloma completed and dose escalation ongoing. The company plans to file an IND for GDT201 in colorectal cancer by year-end and start solid tumor studies for GDT002.PR NewswireFirst Patient Dosed with Gadeta's gamma delta TCR Cell TherapyGadeta B.V., a clinical-stage immunotherapy company headquartered in the Netherlands, has dosed the first patient with GDT-002, its gamma delta TCR-based cell therapy, in a multicenter Phase 1/2 clinical trial for multiple myeloma conducted in collaboration with three U.S. cancer centers. Preclinical studies showed GDT-002 demonstrated activity comparable to BCMA CAR-T in animal models and selectively kills primary, relapsed, and refractory multiple myeloma cells. The company is developing a pipeline of gamma delta TCR-based therapies targeting both liquid and solid tumors, with this trial representing a key milestone in Gadeta's clinical development program.